280 results about "Cell fusion" patented technology

A single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a nociceptive sensory afferent; a dynorphin Targeting Moiety that is capable of binding to a Binding Site on the nociceptive sensory afferent, which Binding Site is capable of undergoing endocytosis to be incorporated into an endosome within the nociceptive sensory afferent; a protease cleavage site at which site the fusion protein is cleavable by a protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the dynorphin Targeting Moiety; and a translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the nociceptive sensory afferent. Nucleic acid sequences encoding the polypeptide fusion proteins, methods of preparing same and uses thereof are also described.

This invention provides: agents determined to be capable of specifically inhibiting the fusion of a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell, but not a T cell-tropic isolate of HIV-1 to a CD4+ cell; and agents determined to be capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 to a CD4+ cell, but not a macrophage-tropic primary isolate of HIV-1 to a CD4+ cell. This invention also provides: agents capable of specifically inhibiting the fusion of a macrophage tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1; and agents capable of specifically inhibiting the fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1. The agents include but are not limited to antibodies. This invention further provides: methods of inhibiting fusion of a macrophage-tropic primary isolate of HIV-1 with a CD+ cell susceptible to infection by a macrophage-tropic primary isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion; and methods of inhibiting fusion of a T cell-tropic isolate of HIV-1 with a CD4+ cell susceptible to infection by a T cell-tropic isolate of HIV-1 which comprises contacting the CD4+ cell with an amount of an agent capable of specifically inhibiting such fusion so as to thereby inhibit such fusion.

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and / or research applications.

The present invention relates to a method for producing a modified foreign chromosome(s) or a fragment(s) thereof, which comprises the steps of: (a) preparing a microcell comprising a foreign chromosome(s) or a fragment(s) thereof, and transferring said foreign chromosome(s) or a fragment(s) into a cell with high homologous recombination efficiency through its fusion with said microcell; (b) in said cell with high homologous recombination efficiency, inserting a targeting vector by homologous recombination into a desired site of said foreign chromosome(s) or a fragment(s) thereof, and / or a desired site of a chromosome(s) derived from said cell with high homologous recombination efficiency, thereby marking said desired site; and (c) in said cell with high homologous recombination efficiency, causing deletion and / or translocation to occur at the marked site of said foreign chromosome(s) or a fragment(s) thereof.

The invention discloses placental villus plate mesenchymal stem cells. An extraction method of the placental villus plate mesenchymal stem cells includes the following steps that 1, a placental villus plate is obtained; 2, blood vessels and villus tissue are removed; 3, the villus plate is cleaned till the blood color disappears; 4, the villus plate is sheared into 0.5-5 mm<2> tissue microblocks, and the tissue microblocks are cleaned; 5, tissue digestive juice containing pancreatin, collagenase II, collagenase IV and hyaluronidase is added for digestion; 6, filtration and centrifugation are carried out; 7, culture is carried out; 8, cell digestion is carried out with 0.25% pancreatin when the cell confluence reaches 70-90%; 9, subculturing is carried out; 10, detection is carried out; 11, cryopreservation is carried out; 12, database building is carried out. According to the method, the steps are simple, and a large number of mesenchymal stem cells can be rapidly obtained from the placental tissue; the separation process does not need too much cleaning operation; the use of antibiotics is omitted, so that the purity of the placental villus plate mesenchymal stem cells obtained after separation is high.

The invention relates to an enrofloxacin monoclonal antibody and application, relates to hybridoma strains thereof, and belongs to the technical field of immunochemistry. The enrofloxacin monoclonal antibody is generated by mouse hybridoma strains 6A4 and 8E6. The preparation method comprises the following steps that: enrofloxacin and carrier proteins BSA, HAS and OVA are coupled by a carbodiimide method to synthesize artificial immunogens EnR-BSA, EnR-HSA and coatingen EnR-OVA; a Balb / c mouse is immunized by the synthesized artificial immunogens EnR-BSA and EnR-HSA; a spleen cell of the immunized mouse is extracted to be fused with a SP2 / O myeloma cell and coated by the coatingen EnR-OVA; indirect ELISA method and indirect competition ELISA method are established to screen the hybridoma strains which can stably secrete specific antibody; the obtained cell strain immunized Balb / c mouse is used to prepare ascites; the ascites is purified by a caprylic acid-ammonium method and an ion exchange method; and valences of antibodies of two purified cell strains reach over 1.024*10 and 1.28*10. The monoclonal antibody has strong specificity, can be applied to preparation of enrofloxacin residue inspection kit and aerosol test strip, and can sensibly and quickly inspect the enrofloxacin residue.

A method for producing a monoclonal antibody and antigen-specific antibody-producing hybridomas using a single antigen-specific B lymphocyte is provided. The method for producing antigen-specific antibody-producing hybridomas comprises selecting a single B lymphocyte reacting specifically with a certain antigen, an “antigen-specific B lymphocyte”, culturing the antigen-specific B lymphocyte selected, and fusing the cultured antigen-specific B lymphocyte with myeloma cells to obtain the hybridomas. The monoclonal antibody is produced with thus obtained hybridomas.

The invention discloses a coupling product of streptomycin and carrier protein, and a preparation method of a streptomycin antibody and an application thereof, which relate to a coupling method of the carrier protein such as keyhole limpet hemocyanin, human serum albumin, cow serum albumin, ovalbumin and the like with streptomycin, and immune BALB / C mouse spleen cells are fused with SP2 / 0 mouse myeloma cells by streptomycin immunogens coupled with the carrier protein, and the streptomycin coupled with the carrier protein is used as a coating antigen for screening positive hybridoma and hybridoma that can steady passage and excrete anti-specificity streptomycin monoclonal antibody can be obtained by the cell clone, and ascites monoclonal antibody is prepared. The prepared monoclonal antibody is used for building a direct competition ELISA method with high specificity, sensitivity and accuracy to the streptomycin and immunity colloidal gold test strips. The coupling of the streptomycin and the carrier protein and the preparation method of the streptomycin monoclonal antibody can provide services for detecting streptomycin residue in foods quickly.